Clinicopathologic Spectrum of NTRK fusion-positive Tumors Detected by Clinical RNA Sequencing Panel

被引：0

作者：

Garcia, Annie ^{[1
]}

Reuther, Jacquelyn ^{[2
]}

Voicu, Horatiu ^{[2
]}

Mohila, Carrie ^{[3
]}

Adesina, Adekunle ^{[2
]}

Schady, Deborah ^{[3
]}

Wang, Wei-Lien Billy ^{[4
]}

Lazar, Alexander ^{[4
]}

Lopez-Terrada, Dolores ^{[2
]}

Lin, Frank ^{[2
]}

Venkatramani, Rajkumar ^{[2
]}

Plon, Sharon ^{[2
]}

Parsons, Williams ^{[2
]}

Fisher, Kevin ^{[2
]}

Roy, Angshumoy ^{[1
]}

机构：

[1] Baylor Coll Med, Houston, TX 77030 USA

[2] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA

[3] Texas Childrens Hosp, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

LABORATORY INVESTIGATION | 2022年 / 102卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

页码：36 / 37

页数：2

共 50 条

[41] Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2
Lu, J.
Blakely, C. M.
Barve, M.
Chung, C. H.
Waqar, S. N.
Hu, X.
Delord, J-P.
Krzakowski, M. J.
Yonemori, K.
Chen, D. T.
Klingbiel, D.
Heinzmann, S.
Le Tourneau, C.
ANNALS OF ONCOLOGY, 2022, 33 : S204 - S205
[42] Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
Bazhenova, L.
Liu, S. V.
Lin, J. J.
Lu, S.
Drilon, A.
Chawla, S. P.
Fakih, M.
Krzakowski, M.
Paz-Ares, L.
Blakely, C.
Buchschacher, G. L., Jr.
Cassier, P.
Fan, Y.
Folprecht, G.
McCallum, S.
Pitcher, B.
Chen, D.
Freund, R.
Springfeld, C.
ANNALS OF ONCOLOGY, 2021, 32 : S598 - S599
[43] Case Report: An NTRK1 fusion-positive embryonal rhabdomyosarcoma: clinical presentations, pathological characteristics and genotypic analyses
Li, Na-Mei
Jiang, Shi-He
Zhou, Peng
Li, Xiao-Hong
FRONTIERS IN ONCOLOGY, 2023, 13
[44] The Use of Zenocutuzumab for NRG1 Fusion-Positive Tumors
Schram, Alison
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (10) : 487 - 489
[45] TRK INHIBITOR TREATMENT PATTERNS IN PATIENTS WITH NTRK FUSION-POSITIVE SOLID TUMORS: A MULTISITE COHORT STUDY AT US ACADEMIC CANCER CENTERS
Willis, C.
Au, T.
Griswold, C.
Schabath, M. B.
Thompson, J.
Malhotra, J.
Ko, G.
Appukkuttan, S.
Warnock, N.
Kong, S.
Hocum, B.
Brixner, D.
Stenehjem, D.
VALUE IN HEALTH, 2022, 25 (12) : S41 - S41
[46] Improving Outcomes in Pediatric NTRK Gene Fusion-Positive Solid Tumors: Importance of Genomic Testing and Targeted Therapy With the TRK Inhibitor Larotrectinib
Laetsch, Theodore W.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (04)
[47] A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Adult Subjects with NTRK Fusion-Positive Tumors.
Drilon, Alexander E.
Hong, David S.
Cruickshank, Scott
Deegan, Maegan
Ku, Nora
Hyman, David Michael
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[48] Entrectinib Approved for NTRK Fusion-Positive Solid Tumors and ROS1-Rearranged Non-Small Cell Lung Cancer
Schuyler, Devon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 610 - 610
[49] Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors (vol 28, pg 1302, 2022)
Demetri, George D.
De Braud, Filippo
Drilon, Alexander
Siena, Salvatore
Patel, Manish R.
Cho, Byoung Chul
Liu, Stephen, V
Ahn, Myung-Ju
Chiu, Chao-Hua
Lin, Jessica J.
Goto, Koichi
Lee, Jeeyun
Bazhenova, Lyudmila
John, Thomas
Fakih, Marwan
Chawla, Sant P.
Dziadziuszko, Rafal
Seto, Takashi
Heinzmann, Sebastian
Pitcher, Bethany
Chen, David
Wilson, Timothy R.
Rolfo, Christian
CLINICAL CANCER RESEARCH, 2022, 28 (10) : 2196 - 2196
[50] Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial
Besse, Benjamin
Baik, Christina
Springfeld, Christoph
Hervieu, Alice
Moreno, Victor
Bazhenova, Lyudmila
Lin, Jessica J.
Camidge, D. Ross
Solomon, Benjamin
Velcheti, Vamsidhar
van der Wekken, Anthonie J.
Felip, Enriqueta
Uprety, Dipesh
Trone, Denise
Stopatschinskaja, Shanna
Cho, Byoung Chul
Drilon, Alexander
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)

← 1 2 3 4 5 →